Cytophage Technologies Proceeds with Non-Brokered Unit Private Placement
Winnipeg, Manitoba — November 5, 2025 — Leads & Copy — Cytophage Technologies Ltd. (TSXV: CYTO, FSE: 70G) announced it will proceed to close its non-brokered unit private placement.
The company has received orders and indications for approximately 6,000,000 units, representing approximately $1.2 million of proceeds. Cytophage anticipates closing the Offering on November 10, 2025, with a secondary tranche on November 17, 2025, if necessary. The company may increase the size of the Offering by up to $600,000 to accommodate additional investor demand.
Cytophage Technologies is dedicated to bacteriophage research, product development, and commercialization. Bacteriophages are viruses that infect and kill bacteria, offering a natural alternative to antibiotics.
The company improves bacteria’s natural predators with environmental and genetic modifications to bring killer solutions to large markets, focusing on animal health for near-term revenue. Cytophage is committed to addressing global antibiotic resistance (AMR), which the WHO predicts will be the leading cause of human mortality by 2050.
For further information, contact Julius Kalcevich, Chief Financial Officer, at julius.kalcevich@cytophage.com or 647 705 5544.
Source: Cytophage Technologies Ltd.
Share this story:
